TY - JOUR
T1 - Comprehensive safety analysis of Venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia
AU - Davids, Matthew S.
AU - Hallek, Michael
AU - Wierda, William
AU - Roberts, Andrew W.
AU - Stilgenbauer, Stephan
AU - Jones, Jeffrey A.
AU - Gerecitano, John F.
AU - Kim, Su Young
AU - Potluri, Jalaja
AU - Busman, Todd
AU - Best, Andrea
AU - Verdugo, Maria E.
AU - Cerri, Elisa
AU - Desai, Monali
AU - Hillmen, Peter
AU - Seymour, John F.
N1 - Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/9/15
Y1 - 2018/9/15
N2 - Purpose: The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del (17p)] or progressive disease following B-cell receptor pathway inhibitors. Patients and Methods: We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three phase I/II studies. Results: Median age was 66 years and 60% had del(17p). Patients had received a median of three prior therapies (range: 0–15); 42% previously received ibrutinib or idelalisib. Median duration of exposure to venetoclax was 16 months (0–56). In the pooled analysis, the most common adverse events (AE) of any grade were diarrhea (41%), neutropenia (40%), nausea (39%), anemia (31%), fatigue (28%), and upper respiratory tract infection (25%). The most common grade 3/4 AEs were neutropenia (37%), anemia (17%), and thrombocytopenia (14%). With the current 5-week ramp-up dosing, the incidence of laboratory TLS was 1.4% (2/166), none had clinical sequelae, and all of these patients were able to ramp-up to a daily dose of 400 mg. Grade 3/4 neutropenia was manageable with growth factor support and dose adjustments; the incidence of serious infections in these patients was 15%. Ten percent of patients discontinued venetoclax due to AEs and 8% died while on study, with the majority of deaths in the setting of disease progression. Conclusions: Venetoclax as a long-term continuous therapy is generally well tolerated in patients with R/R CLL when initiated with the current treatment algorithm.
AB - Purpose: The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del (17p)] or progressive disease following B-cell receptor pathway inhibitors. Patients and Methods: We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three phase I/II studies. Results: Median age was 66 years and 60% had del(17p). Patients had received a median of three prior therapies (range: 0–15); 42% previously received ibrutinib or idelalisib. Median duration of exposure to venetoclax was 16 months (0–56). In the pooled analysis, the most common adverse events (AE) of any grade were diarrhea (41%), neutropenia (40%), nausea (39%), anemia (31%), fatigue (28%), and upper respiratory tract infection (25%). The most common grade 3/4 AEs were neutropenia (37%), anemia (17%), and thrombocytopenia (14%). With the current 5-week ramp-up dosing, the incidence of laboratory TLS was 1.4% (2/166), none had clinical sequelae, and all of these patients were able to ramp-up to a daily dose of 400 mg. Grade 3/4 neutropenia was manageable with growth factor support and dose adjustments; the incidence of serious infections in these patients was 15%. Ten percent of patients discontinued venetoclax due to AEs and 8% died while on study, with the majority of deaths in the setting of disease progression. Conclusions: Venetoclax as a long-term continuous therapy is generally well tolerated in patients with R/R CLL when initiated with the current treatment algorithm.
UR - http://www.scopus.com/inward/record.url?scp=85051540876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051540876&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-17-3761
DO - 10.1158/1078-0432.CCR-17-3761
M3 - Article
C2 - 29895707
AN - SCOPUS:85051540876
SN - 1078-0432
VL - 24
SP - 4371
EP - 4379
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 18
ER -